Tags

Type your tag names separated by a space and hit enter

Allogeneic peripheral blood stem cell transplantation using a fludarabine-based low intensity conditioning regimen for malignant lymphoma.
Bone Marrow Transplant. 2000 May; 25(10):1021-8.BM

Abstract

Relapse is a serious complication following high-dose therapy and autologous bone marrow transplantation (ABMT) for malignant lymphoma (ML). Allogeneic transplantation (alloSCT) is a therapeutic option. However, it is associated with a high incidence of transplant-related organ toxicity and mortality. We recently reported fast engraftment and minimal transplant-related toxicity, using fludarabine-based conditioning with reduced amounts of chemotoxic drugs prior to alloSCT. We now present our experience with 23 heavily treated high risk ML patients who underwent matched alloSCT following the same low intensity conditioning. The patients (20 male, three female) were aged 13-63 years. Nineteen had NHL and four HD (resistant disease 12, partial remission 11). Five were post ABMT. Twenty-two patients had fully matched sibling donors, and one a fully matched unrelated donor. Engraftment was fast. There was no rejection or non-engraftment. Organ toxicity was moderate with no liver or renal toxicity >grade II. Four patients developed >grade II graft-versus-host disease (GVHD). Seven patients died - four of grade III-IV GVHD and severe infections, two of bacterial sepsis, one of pulmonary failure. Ten patients are alive after 22.5 (15-37) months. Survival and disease-free survival at 37 months are both 40%. Probability of relapse is 26%. These encouraging results suggest that alloSCT following fludarabine-based low intensity conditioning in high-risk patients merits further evaluation. Bone Marrow Transplantation (2000).

Authors+Show Affiliations

Department of Bone Marrow Transplantation and Cancer Immunotherapy and Immunobiology Research Center, Hadassah University Hospital, Jerusalem, Israel.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

10828860

Citation

Nagler, A, et al. "Allogeneic Peripheral Blood Stem Cell Transplantation Using a Fludarabine-based Low Intensity Conditioning Regimen for Malignant Lymphoma." Bone Marrow Transplantation, vol. 25, no. 10, 2000, pp. 1021-8.
Nagler A, Slavin S, Varadi G, et al. Allogeneic peripheral blood stem cell transplantation using a fludarabine-based low intensity conditioning regimen for malignant lymphoma. Bone Marrow Transplant. 2000;25(10):1021-8.
Nagler, A., Slavin, S., Varadi, G., Naparstek, E., Samuel, S., & Or, R. (2000). Allogeneic peripheral blood stem cell transplantation using a fludarabine-based low intensity conditioning regimen for malignant lymphoma. Bone Marrow Transplantation, 25(10), 1021-8.
Nagler A, et al. Allogeneic Peripheral Blood Stem Cell Transplantation Using a Fludarabine-based Low Intensity Conditioning Regimen for Malignant Lymphoma. Bone Marrow Transplant. 2000;25(10):1021-8. PubMed PMID: 10828860.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Allogeneic peripheral blood stem cell transplantation using a fludarabine-based low intensity conditioning regimen for malignant lymphoma. AU - Nagler,A, AU - Slavin,S, AU - Varadi,G, AU - Naparstek,E, AU - Samuel,S, AU - Or,R, PY - 2000/6/1/pubmed PY - 2000/8/19/medline PY - 2000/6/1/entrez SP - 1021 EP - 8 JF - Bone marrow transplantation JO - Bone Marrow Transplant VL - 25 IS - 10 N2 - Relapse is a serious complication following high-dose therapy and autologous bone marrow transplantation (ABMT) for malignant lymphoma (ML). Allogeneic transplantation (alloSCT) is a therapeutic option. However, it is associated with a high incidence of transplant-related organ toxicity and mortality. We recently reported fast engraftment and minimal transplant-related toxicity, using fludarabine-based conditioning with reduced amounts of chemotoxic drugs prior to alloSCT. We now present our experience with 23 heavily treated high risk ML patients who underwent matched alloSCT following the same low intensity conditioning. The patients (20 male, three female) were aged 13-63 years. Nineteen had NHL and four HD (resistant disease 12, partial remission 11). Five were post ABMT. Twenty-two patients had fully matched sibling donors, and one a fully matched unrelated donor. Engraftment was fast. There was no rejection or non-engraftment. Organ toxicity was moderate with no liver or renal toxicity >grade II. Four patients developed >grade II graft-versus-host disease (GVHD). Seven patients died - four of grade III-IV GVHD and severe infections, two of bacterial sepsis, one of pulmonary failure. Ten patients are alive after 22.5 (15-37) months. Survival and disease-free survival at 37 months are both 40%. Probability of relapse is 26%. These encouraging results suggest that alloSCT following fludarabine-based low intensity conditioning in high-risk patients merits further evaluation. Bone Marrow Transplantation (2000). SN - 0268-3369 UR - https://www.unboundmedicine.com/medline/citation/10828860/Allogeneic_peripheral_blood_stem_cell_transplantation_using_a_fludarabine_based_low_intensity_conditioning_regimen_for_malignant_lymphoma_ L2 - https://doi.org/10.1038/sj.bmt.1702392 DB - PRIME DP - Unbound Medicine ER -